Zion Market Research has published a new report titled “Hepatorenal Syndrome Treatment Market by Treatment (therapeutics and Surgical Treatment), End users (Hospitals and Clinics, Ambulatory Surgical centers, Academic Research Institutes and Others), Type (Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”.
According to the report, global demand for Hepatorenal Syndrome Treatment Market was valued at approximately USD 10.83 Billion in 2018, and is expected to generate revenue of around USD 15.65 Billion by end of 2025, growing at a CAGR of around 5.45% between 2018 and 2025.
Hepatorenal syndrome or HRS is a medical condition characterized by progressive renal failure in patients with chronic liver disease or cirrhosis of the liver. Cirrhosis is a condition that is life-threatening and painful. HRS patients usually have no known cause of kidney dysfunction as the kidneys themselves do not affect them structurally. It can be considered a “functional” type of kidney impairment. Hepatorenal syndrome patients usually have a variety of symptoms, including abdominal pain, weakness, and discomfort. Those who are severely affected also have signs such as skin and eye white jaundice-like yellowing, heavily swollen liver and spleen, and fluid accumulation called ascites in the abdomen.
Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/hepatorenal-syndrome-treatment-market
Increased awareness of disease and support programs for patients to improve the Hepatorenal syndrome care market. Governments in developed and developing countries carry out awareness campaigns to encourage people to go for early diagnosis of kidney and liver disease to reduce rates of mortality and morbidity. In addition, it is expected to increase awareness of Hepatorenal syndrome diagnosis and treatment, thereby stimulating the growth of the global market for the treatment of Hepatorenal syndrome.
The market for Hepatorenal Syndrome Treatment is segmented based on Treatment, type, end user, and region. Based on Treatment, the market is segmented into Therapeutics and surgical treatment. The segment of therapeutics is expected to rise in the market for hepatorenal syndrome treatment. Consequently, lucrative prospects in the clinical landscape attract the attention of healthcare companies.
Based on the End users, the market is bifurcated Hospitals and Clinics, Ambulatory Surgical centers, Academic Research Institutes, and others. The hospital segment is expected to be the largest segment in the market for hepatorenal syndrome care under the end-user segment. Based on the Type segment, the market is bifurcated into Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.
Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America, Europe, and Asia Pacific are the main regional markets for hepatorenal syndrome care for 2018. The markets for hepatorenal syndrome treatment for North America and Asia Pacific are likely to expand during the forecast period.
Some of the players included in Hepatorenal Syndrome Treatment market are Cumberland Pharmaceuticals, Inc., Orphan Therapeutics, LLC., BioVie Inc. and Mallinckrodt Pharmaceuticals amongst others.
The report segments global Hepatorenal Syndrome Treatment market as follows:
Global Hepatorenal Syndrome Treatment Market: Treatment Segment Analysis
Global Hepatorenal Syndrome Treatment Market: End users Segment Analysis
Global Hepatorenal Syndrome Treatment Market: Type Segment Analysis
Global Hepatorenal Syndrome Treatment Market: Regional Segment Analysis
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/hepatorenal-syndrome-treatment-market